Ovogest

Quick links to important sections

Ovogest

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ovogest

What is Ovogest?

Ovogest is a pharmaceutical preparation containing highly purified human chorionic gonadotropin (hCG), a hormone naturally produced in the human body. In the context of reproductive medicine, it is used to supplement or mimic the hormonal triggers necessary for specific reproductive processes.

Composition and Mechanism

The active ingredient in Ovogest is human chorionic gonadotropin, which is obtained from the urine of pregnant women and undergoes extensive purification. In the female body, hCG acts as an analogue to luteinizing hormone (LH). LH is the primary hormone responsible for the final maturation of the egg and the induction of ovulation from the ovarian follicle. Following ovulation, hCG supports the corpus luteum, the structure responsible for producing progesterone, which is essential for maintaining the early stages of a pregnancy.

In males, the hormone acts on the interstitial cells of the testes. This stimulation facilitates the production of testosterone, which is necessary for the development of secondary sexual characteristics and the maintenance of sperm production.

Clinical Applications

Ovogest is utilized in various therapeutic areas related to fertility and hormonal imbalances:

  • Female Infertility: It is frequently used as part of assisted reproductive technology (ART) protocols to trigger the final maturation of follicles and induce ovulation once the follicles have reached an appropriate size through other treatments.
  • Luteal Phase Support: It may be used to support the function of the corpus luteum in women with a documented deficiency, ensuring adequate progesterone levels.
  • Male Hypogonadism: In men, it is used to treat cases of delayed puberty or hypogonadotropic hypogonadism, where the body does not produce enough of the hormones required for testosterone production and testicular development.
  • Cryptorchidism: It is sometimes used in pediatric cases to treat undescended testes not caused by an anatomical obstruction.

What side effects are possible with Ovogest?

Possible Side Effects and Safety Information: Ovogest

The safety profile for Ovogest (hydroxyprogesterone caproate) focuses primarily on potential long-term risks identified during regulatory review and applies to specific populations.

Official Safety Concerns

The most significant safety concern documented by authoritative government regulatory bodies relates to population-specific safety considerations for individuals exposed to the medicine while in the womb (in utero exposure).

  • Long-Term Risk: The medicine is associated with a possible but unconfirmed increased risk of cancer in people exposed to the medicine in utero. The estimated incidence of this risk is low (less than 25/100,000 person-years).
  • System-Organ Class: This concern involves neoplasms (the formation of tumors/cancer) in the exposed offspring.

Safety-Related Restrictions and Regulatory Status

Official regulatory bodies have assessed the safety profile alongside the medicine's effectiveness.

  • Unfavorable Benefit-Risk Balance: A regulatory review concluded that the overall benefits of Ovogest no longer outweigh the risks for its authorized use (prevention of premature birth).
  • Regulatory Status: This finding led to a formal regulatory recommendation for the suspension of the marketing authorization for Ovogest. This restriction is based on the combination of a lack of demonstrated effectiveness for its authorized use and the possible long-term safety risk to the exposed population.

Adverse Reaction Classification

Adverse events related to the uterine and reproductive systems have been noted in the context of use, though the possible cancer risk is the critical long-term safety concern that determined the regulatory action.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Ovogest (Human Chorionic Gonadotropin) overdose centers on the risk of Ovarian Hyperstimulation Syndrome (OHSS), a condition arising from overstimulation. The primary clinical manifestations documented in official labeling include severe pelvic pain, marked abdominal distension, rapid weight gain, nausea, vomiting, oliguria (decreased urination), and shortness of breath. The physiological systems affected include the vascular system (risk of blood clots), respiratory system (risk of ARDS), and renal system (risk of kidney dysfunction).

Overdose severity is classified as potentially life-threatening due to the risk of severe systemic complications. Life-threatening outcomes explicitly listed in regulatory documents include thromboembolic events (blood clots), acute respiratory distress syndrome (ARDS), and potential progression to renal failure.

Immediate medical attention is required for symptoms indicative of moderate to severe OHSS, such as rapid weight gain, severe abdominal pain, or difficulty breathing. If hyperstimulation is evident, regulatory documents state that HCG administration must be withheld immediately. No specific pharmaceutical antidote is known; therefore, management is focused on symptomatic and supportive treatment with required hospital monitoring in severe cases. The risk of OHSS is specific to women undergoing fertility treatment, and in pediatric male patients, over-exposure may lead to signs of precocious puberty.

Therapeutic Uses of Ovogest

What Ovogest Treats: Main Uses and Benefits

Ovogest is a medication focused on providing supportive symptomatic management across several key domains, contributing to easing the overall symptom load and supporting general well-being during periods of discomfort or stress. It is applied across therapeutic domains where additional symptomatic support is needed. It plays a role in managing symptoms across the following areas:


Easing Episodic Discomfort and Acute Symptoms

Ovogest is generally used in situations involving symptoms that may become intense or disruptive, such as those that cluster into patterns requiring supportive management. The medication is applied in addressing symptoms associated with acute or episodic changes, which helps ease the overall symptom load and offers supportive relief when symptoms become temporarily overwhelming. It is commonly used to help with conditions presenting with systemic discomfort, symptoms that interfere with daily functioning, and symptoms that become more disruptive during flare-ups.

Quick Fact: Relevant for Symptoms that interfere with daily functioning


Addressing Interference with Daily Stability

This medicine is applied in contexts where symptoms create noticeable functional strain or interfere with daily comfort. Ovogest provides symptomatic assistance that may help patients cope more steadily with symptom fluctuations and supports the patient during episodes where functional stability becomes affected. This makes it relevant for easing conditions involving episodic or fluctuating manifestations, as well as situations marked by temporary physiological imbalance.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ovogest?

This section outlines the official eligibility rules for Ovogest (Human Chorionic Gonadotropin) as documented in governmental regulatory sources.


Populations Contraindicated

Ovogest must not be used in patients with a known hypersensitivity to gonadotropins, precocious puberty, androgen-dependent neoplasms (like prostatic carcinoma), or tumors of the hypothalamus or pituitary gland. Use is prohibited in women with primary ovarian failure (high serum FSH), malignant tumors of the reproductive organs, or abnormal vaginal bleeding of undetermined origin.


Age-Related and Conditional Eligibility

Safety and effectiveness have not been established in children below the age of four, and clinical data is insufficient for older adults (age 65 and over). Use is restricted with caution in patients with conditions aggravated by fluid retention, such as cardiac or renal disease, epilepsy, or asthma. The medicine must be withheld if there is evidence that a woman is developing Ovarian Hyperstimulation Syndrome (OHSS).


Pregnancy and Lactation

Ovogest should not be used during established pregnancy as regulatory labeling states it may cause fetal harm. Caution should be exercised during lactation, as it is not known whether the drug is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Ovogest is primarily defined by its metabolic pathway, specifically its clearance through the Cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. Official regulatory documents identify specific categories of medicinal products that may alter the drug’s concentration in the body.

Pharmacokinetic Interactions

Co-administration with potent CYP3A4 inducers (medicines that accelerate the enzyme’s activity) may lead to a significant decrease in Ovogest plasma concentration, potentially diminishing its intended effect. Examples of medicines in this class include certain antiepileptics (such as carbamazepine, phenytoin, and barbiturates) and anti-infectives (such as rifampicin and certain antiretrovirals like efavirenz).

Conversely, co-administration with potent CYP3A4 inhibitors (medicines that block the enzyme’s activity) can lead to a significant increase in Ovogest plasma concentration. This interaction requires close monitoring. Examples of inhibitors include certain antifungal agents (such as ketoconazole and itraconazole) and macrolide antibiotics (such as clarithromycin).

Other Product Interactions

Conditions leading to impaired absorption of the oral formulation, such as severe episodes of vomiting or diarrhea, are documented as non-metabolic factors that may reduce the therapeutic exposure to Ovogest. The concurrent use of strong CYP3A4 inducers generally results in a regulatory restriction to avoid co-administration or require use of alternative therapy.

Mechanism of Action

Ovogest (Choriogonadotropin) is a glycoprotein that structurally and functionally mimics the endogenous Luteinizing Hormone (LH). Its primary biological target is the Lutropin-Choriogonadotropic Hormone Receptor (LHCGR), which is predominantly expressed on the surface of ovarian theca and granulosa cells. Ovogest acts as a full agonist at this G-protein coupled receptor.

Binding to LHCGR initiates a classic mechanistic cascade: it stimulates adenylate cyclase activity via G-protein coupling, resulting in a rapid, substantial increase in the intracellular concentration of cyclic adenosine monophosphate (cAMP). Elevated cAMP levels subsequently activate Protein Kinase A (PKA). PKA phosphorylates specific intracellular proteins, which collectively modulate gene transcription and enzymatic activities within the cell. This signal transduction pathway triggers the final stages of follicular maturation and the resumption of oocyte meiosis. At a system-level physiological consequence, this action provides the signal necessary for the sequence of events analogous to the natural mid-cycle LH surge.

Dosage and Administration Information

Ovogest (Human Chorionic Gonadotropin) is administered solely by injection, using either the intramuscular (IM) or subcutaneous (SC) route after proper preparation. Since the medicine is supplied as a lyophilized powder, it must first be reconstituted using the sterile solvent provided in the package. The mixing process requires the vial to be gently swirled until the powder dissolves; shaking the solution is advised against to maintain the stability of the hormone.

The usage schedule depends entirely on the application. For use as an ovulation trigger, the established regimen involves a single, acute injection typically dosed between 5,000 and 10,000 International Units. This contrasts with its use for stimulating spermatogenesis in males with hypogonadism, which follows a long-term, intermittent schedule. These regimens often involve injections ranging from 500 to 4,000 International Units, administered two to three times per week over treatment courses that may span six months or longer.

Dosing for prepubertal patients, such as those treated for specific conditions, follows lower-dose, age-specific schedules determined by clinical factors. The medicine is not typically taken with respect to meals, but strict adherence to the required frequency or the one-time cyclic trigger is central to the established protocol. The reconstituted solution must be visually inspected before use, and any unused portion of single-use vials must be discarded.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ovogest


Evidence for use in Reducing Postmenopausal Hot Flashes

Ovogest was studied in research settings focused on postmenopausal hot flashes, which are conditions characterized by fluctuating or episodic manifestations. The research exploring this use generally involved controlled clinical trials where changes in hot flash frequency and intensity were observed in women following menopause. These studies were evaluated in research contexts involving fluctuating or unstable symptoms, with the goal of tracking outcomes related to physical discomfort.

The findings from these clinical trials generally describe patterns observed when Ovogest was used, including changes in how hot flashes were reported by participants during the study periods. The research describes patterns where women who were observed in these studies reported fewer hot flash episodes or less intense discomfort compared to those receiving a placebo (an inactive substance). These findings describe patterns observed in the studies over defined time intervals.


Evidence for use in Managing Symptoms of Endometriosis-Related Pain

Research has explored Ovogest's application in women with conditions involving periods of heightened symptoms related to endometriosis-related pain. These studies were evaluated in contexts that focused on patient-reported outcomes describing perceived discomfort and outcomes linked to inflammatory or irritative states.

The research examined whether participants experienced changes in their daily pain scores and in their overall outcomes reflecting daily functioning or activity level. The data show patterns related to changes in these reported outcomes during the research studies. Specifically, studies conducted during periods of increased symptom activity suggest that research into Ovogest may provide insight into how symptoms evolved in the observed populations when facing episodic or acute changes in their condition.


Long-term Studies and Follow-up

Currently, long-term effects are not fully established for Ovogest. While studies contribute to the broader evidence landscape by providing insight into short-term changes, the data for long-term outcomes remains insufficient. The available research has typically had follow-up durations that were limited.

This limitation means that certainty remains low regarding the lasting nature of the observed changes in both hot flashes and endometriosis-related pain. Research is ongoing to provide more comprehensive information about these extended patterns.


Evidence in Special Populations

Special populations include groups like older adults or individuals with certain pre-existing medical conditions, where study results may show different patterns of change. For older adults, the sample sizes were modest in the studies, and results apply only to the populations studied. Therefore, the data for this group remain insufficient for a comprehensive overview.

There is currently limited or insufficient research available for women who are pregnant or nursing, and data for these specific populations are still emerging.


What is Still Uncertain about Ovogest

One key uncertainty is the overall long-term profile, as long-term effects are not fully established, and follow-up durations were limited in many studies. Furthermore, comparative evidence is lacking that directly evaluates Ovogest against other available methods for managing these conditions. Additionally, some of the findings were mixed across different studies, leading to uncertainty in how to interpret the results consistently. The evidence highlights that these research results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Ovogest (FAQ)

Q: How quickly does Ovogest start working after I take it?

Official product information, based on studies of its pharmacokinetics (how the body handles the medicine), indicates how quickly it enters the bloodstream. Following an intramuscular injection, the medicine typically reaches its maximum concentration in the blood within 4 to 12 hours.

Q: How long does the effect of one dose of Ovogest typically last?

Studies tracking the drug's presence in the body provide an estimate for how long it circulates. The half-life, which is the time it takes for half of the dose to be naturally cleared, is generally reported as being between 29 and 37 hours.

Q: Can Ovogest be used for conditions other than what's listed in the main uses?

Regulatory labels state that the drug has not been proven to be effective for purposes outside of its approved indications. Official documents specifically warn against using the medicine, such as for weight loss, as its effectiveness for unapproved uses has not been demonstrated.

Q: What happens if I forget to take a dose of Ovogest?

Patient labeling instructs that if a dose is missed, a healthcare provider should be contacted immediately for guidance. The specific course of action is determined by the healthcare provider based on the individual treatment schedule and the underlying medical condition.

Q: Why is it important to take Ovogest at the same time each day?

For long-term regimens, strict adherence to a consistent schedule is necessary to maintain predictable and stable levels of the hormone in the body. This consistent concentration is necessary to support the intended physiological effect on the reproductive system.

Q: Can consuming alcohol affect how Ovogest works?

Clinical studies examining the medicine’s effects have provided some insight into potential interactions. Evidence suggests that short-term, heavy consumption of alcohol may alter the testicular response to the medicine in male patients.

Q: Are changes in mood a common side effect reported for Ovogest?

Official product information indicates that changes in mood have been reported by users. Commonly reported side effects include emotional disturbances, feelings of depression, irritability, and restlessness.

Q: Is it normal to feel slightly nauseous when first starting Ovogest?

Studies and regulatory summaries classify nausea as a commonly reported undesirable effect. This effect has been noted particularly in clinical trials for certain forms of the hormone.

Q: Does Ovogest cause weight gain or weight loss for most users?

Official regulatory warnings explicitly state that the drug has not been demonstrated to be effective as a treatment for weight loss. Fluid retention, known as edema, is a commonly reported side effect that may contribute to temporary changes in weight.

Q: How often are side effects reported in research studies of Ovogest?

Regulatory documents classify the frequency of adverse effects based on clinical trial data. Some common reactions, such as injection site issues, headaches, and nausea, are reported as 'very common,' occurring in 10% or more of patients.

Q: Is Ovogest approved for use in children or teenagers?

The medicine is approved for specific uses in males, including the treatment of prepubertal cryptorchidism (undescended testicles) when it is not caused by an anatomical issue. It is also used to treat hypogonadism in males, a condition characterized by deficient reproductive function.

Q: Does taking Ovogest affect my ability to drive or operate machinery?

Side effects such as headache, dizziness, and fatigue (tiredness) are reported in official product information. Official labeling states that if individuals experience these side effects, performing tasks that require focus and alertness may be impaired.

Q: What should I do if a potential side effect becomes bothersome?

Patient information instructs that the healthcare provider should be contacted immediately if any side effects become bothersome, do not go away, or if symptoms of a serious condition develop. This allows for medical monitoring and appropriate guidance regarding the symptoms.

Q: Can I stop taking Ovogest suddenly, or should it be gradual?

Any decision to stop taking the medicine or change the dosage should only be made under the direct supervision of a healthcare provider. While the one-time ovulation trigger use is naturally an abrupt dosage cessation, long-term use requires medical evaluation before stopping.

Q: Does Ovogest affect the results of common lab tests?

Due to its active ingredient, the medicine can interfere with the results of certain laboratory procedures. Official labels indicate that the drug can interfere with immunological tests for pregnancy (blood or urine tests) for approximately 10 days after administration.

Q: Why do some people report feeling tired after starting Ovogest?

According to official product information and clinical summaries, fatigue, or a general feeling of tiredness, is listed as a commonly reported undesirable effect associated with the use of the medicine.

Q: Is Ovogest a controlled substance in the US or other countries?

In the United States, prescription human chorionic gonadotropin (hCG) is not listed as a federally controlled substance. However, its use and distribution are highly regulated by government bodies, and is subject to strict governmental regulation.

Q: What is the estimated time for Ovogest to clear completely from the body?

Based on pharmacokinetics, the medicine has a terminal half-life typically between 29 and 37 hours. This calculation suggests the medicine is typically eliminated from the body within a period of approximately 6 to 10 days.

Q: Can Ovogest worsen pre-existing mental health conditions?

The medicine has been associated with emotional disturbances, including depression and irritability, as noted in regulatory summaries of side effects. For patients who have a history of pre-existing mood disorders, monitoring by a healthcare professional is recommended.

Q: Why does the packaging of Ovogest have a warning about blood clots?

Regulatory documents require a warning because the medicine may cause thromboembolic events, which is the medical term for blood clots forming in arteries or veins. These events are a potential serious risk, which could lead to conditions like deep vein thrombosis.

Q: Is it safe to exercise heavily while taking Ovogest?

For women undergoing treatment, official labels require monitoring for Ovarian Hyperstimulation Syndrome (OHSS). Official guidance indicates that if ovarian enlargement is noted, temporary refraining from strenuous physical activity may be necessary to reduce the potential for complications, a determination made by the treating provider.

How should Ovogest be stored and disposed of?

How to Store and Dispose of Ovogest

Ovogest (chorionic gonadotropin) requires different storage based on its formulation phase.

Storage Requirements

Product Form Temperature Range Protection Requirement
Unmixed Powder Controlled Room Temperature (20 C to 25 C) Protect from light; keep in original container.
Reconstituted Solution Refrigerated (2 C to 8 C) Do not freeze; discard after 30 days.

Handling and Disposal

Once reconstituted, the solution must not be frozen and should be visually inspected prior to use. Keep all vials and components out of the sight and reach of children. Dispose of all used needles and syringes immediately in a closeable, puncture-resistant sharps container. Unused or expired Ovogest must not be flushed down a toilet or thrown in household trash; follow local regulations or use drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ovogest found in:

A-Z Index: